Briacell Therapeutics

BCTX · TORONTO

$3.44+$0.025 (+0.73%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $3.41

BCTX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 9, 2026

Bull case

BriaCell Therapeutics Corp has received a non-dilutive $2 million grant from the US National Cancer Institute (NCI) aimed at advancing its Bria-PROS+ toward clinical stages, specifically to assist in manufacturing clinical supply and support Phase 1/2a development for metastatic prostate cancer. This funding will significantly accelerate the clinical development of its existing immunotherapy program, Bria-OTS, which is already in a Phase 1/2 trial for breast and prostate cancer. The positive momentum from this grant, combined with BriaCell's focus on innovative immunotherapy treatments, supports a favorable outlook for the company's stock as it progresses in enhancing cancer treatment options.

Bear case

BriaCell Therapeutics faces multiple challenges that contribute to a negative outlook on its stock, including potential safety signals from its clinical programs and the possibility of lower-than-expected efficacy, which may hinder their ability to achieve statistical significance in studies. Additionally, the company anticipates requiring approximately $120 million in additional financing through 2037, along with further capital needed by fiscal year 2026, indicating significant funding pressures ahead. Furthermore, the competitive landscape presents a risk of greater-than-expected competition from other cancer treatments in development, complicating BriaCell's positioned therapies in the market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.